|
1
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kampan NC, Madondo MT, McNally OM, Quinn M
and Plebanski M: Paclitaxel and its evolving role in the management
of ovarian cancer. BioMed Res Int. 2015:4130762015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brouwer-Visser J, Lee J, McCullagh K,
Cossio MJ, Wang Y and Huang GS: Insulin-like growth factor 2
silencing restores taxol sensitivity in drug resistant ovarian
cancer. PLoS One. 9:e1001652014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kelleher FC, O'Sullivan H, Smyth E,
McDermott R and Viterbo A: Fibroblast growth factor receptors,
developmental corruption and malignant disease. Carcinogenesis.
34:2198–2205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hughes SE: Differential expression of the
fibroblast growth factor receptor (FGFR) multigene family in normal
human adult tissues. J Histochem Cytochem. 45:1005–1019. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Touat M, Ileana E, Postel-Vinay S, André F
and Soria JC: Targeting FGFR signaling in cancer. Clin Cancer Res.
21:2684–2694. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wesche J, Haglund K and Haugsten EM:
Fibroblast growth factors and their receptors in cancer. Biochem J.
437:199–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hallinan N, Finn S, Cuffe S, Rafee S,
O'Byrne K and Gately K: Targeting the fibroblast growth factor
receptor family in cancer. Cancer Treat Rev. 46:51–62. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Katoh M: FGFR inhibitors: Effects on
cancer cells, tumor micro-environment and whole-body homeostasis
(Review). Int J Mol Med. 38:3–15. 2016.PubMed/NCBI
|
|
12
|
Helsten T, Elkin S, Arthur E, Tomson BN,
Carter J and Kurzrock R: The FGFR landscape in cancer: Analysis of
4,853 tumors by next-generation sequencing. Clin Cancer Res.
22:259–267. 2016. View Article : Google Scholar
|
|
13
|
Xue M, Cao X, Zhong Y, Kuang D, Liu X,
Zhao Z and Li H: Insulin-like growth factor-1 receptor (IGF-1R)
kinase inhibitors in cancer therapy: Advances and perspectives.
Curr Pharm Des. 18:2901–2913. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Asati V, Mahapatra DK and Bharti SK:
PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as
anticancer agents: Structural and pharmacological perspectives. Eur
J Med Chem. 109:314–341. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen J, Elfiky A, Han M, Chen C and Saif
MW: The role of Src in colon cancer and its therapeutic
implications. Clin Colorectal Cancer. 13:5–13. 2014. View Article : Google Scholar
|
|
16
|
Schultze SM, Hemmings BA, Niessen M and
Tschopp O: PI3K/AKT, MAPK and AMPK signalling: Protein kinases in
glucose homeostasis. Expert Rev Mol Med. 14:e12012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dillon LM and Miller TW: Therapeutic
targeting of cancers with loss of PTEN function. Curr Drug Targets.
15:65–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Franke TF, Yang SI, Chan TO, Datta K,
Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein
kinase encoded by the Akt proto-oncogene is a target of the
PDGF-activated phosphatidylinositol 3-kinase. Cell. 81:727–736.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu J, Feng X, Zhang B, Li J, Xu X, Liu J,
Wang X, Wang J and Tong X: Blocking the bFGF/STAT3 interaction
through specific signaling pathways induces apoptosis in
glioblastoma cells. J Neurooncol. 120:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kohn AD, Kovacina KS and Roth RA: Insulin
stimulates the kinase activity of RAC-PK, a pleckstrin homology
domain containing ser/thr kinase. EMBO J. 14:4288–4295.
1995.PubMed/NCBI
|
|
21
|
Henson ES and Gibson SB: Surviving cell
death through epidermal growth factor (EGF) signal transduction
pathways: Implications for cancer therapy. Cell Signal.
18:2089–2097. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hemmings BA and Restuccia DF: PI3K-PKB/Akt
pathway. Cold Spring Harb Perspect Biol. 4:a0111892012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim D, Dan HC, Park S, Yang L, Liu Q,
Kaneko S, Ning J, He L, Yang H, Sun M, et al: AKT/PKB signaling
mechanisms in cancer and chemoresistance. Front Biosci. 10:975–987.
2005. View Article : Google Scholar
|
|
25
|
Mehta G, Hsiao AY, Ingram M, Luker GD and
Takayama S: Opportunities and challenges for use of tumor spheroids
as models to test drug delivery and efficacy. J Control Release.
164:192–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hickman JA, Graeser R, de Hoogt R, Vidic
S, Brito C, Gutekunst M and van der Kuip H; IMI PREDECT Consortium:
Three-dimensional models of cancer for pharmacology and cancer cell
biology: Capturing tumor complexity in vitro/ex vivo. Biotechnol J.
9:1115–1128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hirschhaeuser F, Menne H, Dittfeld C, West
J, Mueller-Klieser W and Kunz-Schughart LA: Multicellular tumor
spheroids: An underestimated tool is catching up again. J
Biotechnol. 148:3–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ke N, Albers A, Claassen G, Yu DH,
Chatterton JE, Hu X, Meyhack B, Wong-Staal F and Li QX: One-week
96-well soft agar growth assay for cancer target validation.
Biotechniques. 36:826–828. 830832–833. 2004.PubMed/NCBI
|
|
29
|
Cao D, Kishida S, Huang P, Mu P, Tsubota
S, Mizuno M and Kadomatsu K: A new tumorsphere culture condition
restores potentials of self-renewal and metastasis of primary
neuroblastoma in a mouse neuroblastoma model. PLoS One.
9:e868132014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weiswald LB, Bellet D and Dangles-Marie V:
Spherical cancer models in tumor biology. Neoplasia. 17:1–15. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahmed N and Stenvers KL: Getting to know
ovarian cancer ascites: Opportunities for targeted therapy-based
translational research. Front Oncol. 3:2562013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu D, Wolf JK, Scanlon M, Price JE and
Hung MC: Enhanced c-erbB-2/neu expression in human ovarian cancer
cells correlates with more severe malignancy that can be suppressed
by E1A. Cancer Res. 53:891–898. 1993.PubMed/NCBI
|
|
33
|
Dieci MV, Arnedos M, Andre F and Soria JC:
Fibroblast growth factor receptor inhibitors as a cancer treatment:
From a biologic rationale to medical perspectives. Cancer Discov.
3:264–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ornitz DM and Itoh N: The fibroblast
growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol.
4:215–266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamada O, Ozaki K, Akiyama M and Kawauchi
K: JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase
transcriptionally and posttranslationally in ATL cells. Mol Cancer
Ther. 11:1112–1121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gu YJ, Sun WY, Zhang S, Li XR and Wei W:
Targeted blockade of JAK/STAT3 signaling inhibits proliferation,
migration and collagen production as well as inducing the apoptosis
of hepatic stellate cells. Int J Mol Med. 38:903–911.
2016.PubMed/NCBI
|
|
37
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee JM, Mhawech-Fauceglia P, Lee N,
Parsanian LC, Lin YG, Gayther SA and Lawrenson K: A
three-dimensional microen-vironment alters protein expression and
chemosensitivity of epithelial ovarian cancer cells in vitro. Lab
Invest. 93:528–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liao J, Qian F, Tchabo N,
Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB,
Morrison CD, et al: Ovarian cancer spheroid cells with stem
cell-like properties contribute to tumor generation, metastasis and
chemotherapy resistance through hypoxia-resistant metabolism. PLoS
One. 9:e849412014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He QZ, Luo XZ, Wang K, Zhou Q, Ao H, Yang
Y, Li SX, Li Y, Zhu HT and Duan T: Isolation and characterization
of cancer stem cells from high-grade serous ovarian carcinomas.
Cell Physiol Biochem. 33:173–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang L, Mezencev R, Bowen NJ, Matyunina LV
and McDonald JF: Isolation and characterization of stem-like cells
from a human ovarian cancer cell line. Mol Cell Biochem.
363:257–268. 2012. View Article : Google Scholar
|
|
42
|
Moon SH, Kim DK, Cha Y, Jeon I, Song J and
Park KS: PI3K/Akt and Stat3 signaling regulated by PTEN control of
the cancer stem cell population, proliferation and senescence in a
glioblastoma cell line. Int J Oncol. 42:921–928. 2013.PubMed/NCBI
|
|
43
|
Han Z, Feng J, Hong Z, Chen L, Li W, Liao
S, Wang X, Ji T, Wang S, Ma D, et al: Silencing of the STAT3
signaling pathway reverses the inherent and induced chemoresistance
of human ovarian cancer cells. Biochem Biophys Res Commun.
435:188–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T,
Hu W, Yan Y, Feng J, Liao S, et al: A potent oncolytic adenovirus
selectively blocks the STAT3 signaling pathway and potentiates
cisplatin antitumor activity in ovarian cancer. Hum Gene Ther.
23:32–45. 2012. View Article : Google Scholar
|
|
45
|
Zhang X, Liu P, Zhang B, Wang A and Yang
M: Role of STAT3 decoy oligodeoxynucleotides on cell invasion and
chemosensitivity in human epithelial ovarian cancer cells. Cancer
Genet Cytogenet. 197:46–53. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Fujiwara Y, Takaishi K, Nakao J, Ikeda T,
Katabuchi H, Takeya M and Komohara Y: Corosolic acid enhances the
antitumor effects of chemotherapy on epithelial ovarian cancer by
inhibiting signal transducer and activator of transcription 3
signaling. Oncol Lett. 6:1619–1623. 2013.PubMed/NCBI
|
|
47
|
Chang JY, Wang C, Liu J, Huang Y, Jin C,
Yang C, Hai B, Liu F, D'Souza RN, McKeehan WL, et al: Fibroblast
growth factor signaling is essential for self-renewal of dental
epithelial stem cells. J Biol Chem. 288:28952–28961. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Guagnano V, Kauffmann A, Wöhrle S, Stamm
C, Ito M, Barys L, Pornon A, Yao Y, Li F, Zhang Y, et al: FGFR
genetic alterations predict for sensitivity to NVP-BGJ398, a
selective pan-FGFR inhibitor. Cancer Discov. 2:1118–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheng T, Roth B, Choi W, Black PC, Dinney
C and McConkey DJ: Fibroblast growth factor receptors-1 and -3 play
distinct roles in the regulation of bladder cancer growth and
metastasis: Implications for therapeutic targeting. PLoS One.
8:e572842013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ueno NT, Bartholomeusz C, Herrmann JL,
Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D,
et al: E1A-mediated paclitaxel sensitization in
HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis
involving the caspase-3 pathway. Clin Cancer Res. 6:250–259.
2000.PubMed/NCBI
|
|
51
|
Galkin AV, Melnick JS, Kim S, Hood TL, Li
N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, et al:
Identification of NVP-TAE684, a potent, selective, and efficacious
inhibitor of NPM-ALK. Proc Natl Acad Sci USA. 104:270–275. 2007.
View Article : Google Scholar :
|
|
52
|
Buchdunger E, Zimmermann J, Mett H, Meyer
T, Müller M, Druker BJ and Lydon NB: Inhibition of the Abl
protein-tyrosine kinase in vitro and in vivo by a
2-phenylaminopyrimidine derivative. Cancer Res. 56:100–104.
1996.PubMed/NCBI
|
|
53
|
Ranza E, Mazzini G, Facoetti A and Nano R:
In-vitro effects of the tyrosine kinase inhibitor imatinib on
glioblastoma cell proliferation. J Neurooncol. 96:349–357. 2010.
View Article : Google Scholar
|
|
54
|
Heinrich MC, Griffith DJ, Druker BJ, Wait
CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine
kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Blood. 96:925–932. 2000.PubMed/NCBI
|
|
55
|
Sims JT, Ganguly SS, Bennett H, Friend JW,
Tepe J and Plattner R: Imatinib reverses doxorubicin resistance by
affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT
pathways and by inhibiting ABCB1. PLoS One. 8:e555092013.
View Article : Google Scholar
|
|
56
|
Cole C, Lau S, Backen A, Clamp A, Rushton
G, Dive C, Hodgkinson C, McVey R, Kitchener H and Jayson GC:
Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in
ovarian cancer. Cancer Biol Ther. 10:495–504. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gritsina G, Xiao F, O'Brien SW, Gabbasov
R, Maglaty MA, Xu RH, Thapa RJ, Zhou Y, Nicolas E, Litwin S, et al:
Targeted blockade of JAK/STAT3 signaling inhibits ovarian carcinoma
growth. Mol Cancer Ther. 14:1035–1047. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
McCann GA, Naidu S, Rath KS, Bid HK,
Tierney BJ, Suarez A, Varadharaj S, Zhang J, Hideg K, Houghton P,
et al: Targeting constitutively-activated STAT3 in hypoxic ovarian
cancer, using a novel STAT3 inhibitor. Oncoscience. 1:216–228.
2014. View Article : Google Scholar
|
|
59
|
Wen W, Liang W, Wu J, Kowolik CM, Buettner
R, Scuto A, Hsieh MY, Hong H, Brown CE, Forman SJ, et al: Targeting
JAK1/STAT3 signaling suppresses tumor progression and metastasis in
a peritoneal model of human ovarian cancer. Mol Cancer Ther.
13:3037–3048. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kobayashi A, Tanizaki Y, Kimura A, Ishida
Y, Nosaka M, Toujima S, Kuninaka Y, Minami S, Ino K and Kondo T:
AG490, a Jak2 inhibitor, suppressed the progression of murine
ovarian cancer. Eur J Pharmacol. 766:63–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Desoize B and Jardillier J: Multicellular
resistance: A paradigm for clinical resistance? Crit Rev Oncol
Hematol. 36:193–207. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yoshida Y, Kurokawa T, Nishikawa Y, Orisa
M, Kleinman HK and Kotsuji F: Laminin-1-derived scrambled peptide
AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids
and improves the efficacy of cisplatin. Int J Oncol. 32:673–681.
2008.PubMed/NCBI
|
|
63
|
Casey RC, Burleson KM, Skubitz KM,
Pambuccian SE, Oegema TR Jr, Ruff LE and Skubitz AP: Beta
1-integrins regulate the formation and adhesion of ovarian
carcinoma multicellular spheroids. Am J Pathol. 159:2071–2080.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Sodek KL, Ringuette MJ and Brown TJ:
Compact spheroid formation by ovarian cancer cells is associated
with contractile behavior and an invasive phenotype. Int J Cancer.
124:2060–2070. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Thibault B, Castells M, Delord JP and
Couderc B: Ovarian cancer microenvironment: Implications for cancer
dissemination and chemoresistance acquisition. Cancer Metastasis
Rev. 33:17–39. 2014. View Article : Google Scholar
|
